ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. It primarily develops sepofarsen that is in phase II/III clinical trial illuminate trial for treating leber congenital amaurosis 10 disease; and ultevursen, which is in phase II/III clinical trial to treat USH2A-mediated retinitis pigmentosa and usher syndrome. The company also engages in the developing of Axiomer RNA base-editing platform technology. It has a license agreement with Radboud University Medical Center, Inserm Transfert SA, Ionis Pharmaceuticals, Inc., and Leiden University Medical Center, as well as license and research collaboration with Eli Lilly and Company for the discovery, development, and commercialization of potential new medicines for genetic disorders in the liver and nervous system. ProQR Therapeutics N.V. was incorporated in 2012 and is headquartered in Leiden, the Netherlands.
P/B ratio for ProQR Therapeutics N.V. (PRQR)
P/B ratio as of 2023: 3.51
According to ProQR Therapeutics N.V.'s latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 3.51. At the end of 2022 the company had a P/B ratio of 3.78.
P/B ratio history for ProQR Therapeutics N.V. from 2012 to 2023
P/B ratio at the end of each year
| Year | P/B ratio |
|---|---|
| 2023 | 3.51 |
| 2022 | 3.78 |
| 2021 | 3.97 |
| 2020 | 3.01 |
| 2019 | 3.84 |
| 2018 | 5.04 |
| 2017 | 1.77 |
| 2016 | 2.04 |
| 2015 | 2.08 |
| 2014 | 1.81 |
| 2013 | -2672.74 |
| 2012 | 0.00 |